Q3 2025 Management View CEO Sean Nolan stated, “The recent regulatory clarity and progress we've achieved, which was enabled ...
The stock of Precigen has surged after FDA approval of Papzimeos, the first therapy for recurrent respiratory papillomatosis, granting a significant first-mover advantage. PGEN's Papzimeos ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback